|Day Low/High||157.29 / 171.25|
|52 Wk Low/High||117.34 / 497.49|
Several sessions over the past 10 days have seen increased trading volume at the NYSE, but not the Nasdaq, and for the S&P 500, but not the Nasdaq Composite. Is this professional risk reduction?
Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Plus, there's talk of a possible combination of Advanced Micro Devices and Xilinx.
One day after deciding that we still could not confirm the market's uptrend, we are forced to ask the opposite.
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
Suddenly, both sides realize that they have played politics and the people had noticed. Not those two from Tuesday night. Thankfully.
Neither candidate seems to be the enemy of the market -- at least not yet.
I see no reason to flee this name, therefore, I am not.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Being scared of a pullback isn't 'expensive' or 'stupid'. It's just good investing.
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Also, several scheduled events this week, election risk, earnings to watch.
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
An effective Covid-19 will be a game-changer, but charts say the bottom-line impact may not be as significant as previously believed.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
Plus, Veeva Systems reports stellar results and ups its guidance.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Plus, quick looks at Joe Biden's VP choice, the latest on the Covid-19 vaccine front and Tesla's stock split.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
The whole group has run and the guidance from Clorox does show, more than anything, that nobody knows.
Plus, Russia could provide a real-time clinical trial of a coronavirus vaccine.
Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.
In a 'normal' recession, these would be real losers -- but right now? They look like numero 'UNO'.
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.